Published on : Jul 13, 2017
Albany, New York, July 13, 2017: In the human body, the skeletal system provides a strong framework upon which muscles, tissues and organs attach. But due to the rising incidences of skeletal diseases around the world has directly affected the pipeline development of its treatment drug. Considering this fact, a new pipeline study, titled “Skeletal Disease Drug Development Pipeline Review, 2017” has been published to the online repository of Market Research Hub (MRH). The report provides comprehensive information on the therapeutics under development. Moreover, key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA) are also mentioned.
Through this assessment, the study attempts to present an in-depth assessment of the therapeutic market on the basis of its past performance and its current status. Currently, there are very few specific therapeutic interventions to prevent, halt or modify skeletal disease progression and therefore the generation of new and effective treatments requires novel and innovative research that can identify tractable therapeutic targets and biomarkers for these diseases.
The skeleton as an organ is widely distributed throughout the entire vertebrate body. The study majorly focuses on the skeletal diseases that are rising frequently such as Osteoarthritis, Osteoporosis and Post-Menopausal Osteoporosis. Of these, OA is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Osteoporosis is one disease of the skeletal system. It is characterized by an abnormally high decrease in the amount of bone tissue in the skeleton. In osteoporosis, bone loses calcium, becomes thinner and may disappear completely. On the other hand, Postmenopausal Osteoporosis is the most common subtype of osteoporosis and affects many women after menopause. Prevention and treatment include calcium and vitamin D, exercise, and other osteoporosis medications.
Moving further, through this analysis, the readers will be able to understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration for each given skeletal disease. The research further identifies that for the most common bone diseases, drugs that prevent bone breakdown have been shown to be effective in reducing the risk of future fractures. These drugs not only slow any further weakening of the skeleton but also allow for some repair of bone mass and strength.
Later in the report, the companies involved in the therapeutics and drug development of skeletal diseases are listed. Some of them are Amura Holdings Ltd., Asklepios BioPharmaceutical Inc, Bone Therapeutics SA, Addex Therapeutics Ltd., Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, Cellular Biomedicine Group Inc., Zydus Cadila Healthcare Ltd., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., Ligand Pharmaceuticals Inc, Oncobiologics Inc. and others. For each company, the dormant, as well as discontinued projects currently in pipeline, are described in the study.
Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1217018
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org